Volume 11, Number 5 (July 2020)

A Decade of JADPRO

Using Social Media as a Platform for Increasing Knowledge of Lung Cancer Screening in High-Risk Patients

Background: Uptake in lung cancer screening for high-risk patients remains low. Eligible patients may not know that this preventive service is available and covered by insurance. Objectives: The objective of this study was to explore usi...

Nutritional Risk in Cancer Patients 65 and Older Undergoing Systemic Phase I Treatment

Malnutrition is common in cancer patients and recognized as an important component of adverse outcomes, including increased morbidity, mortality, and decreased quality of life (QOL). Quality of life is an overarching term for quality of ...

Nausea and Vomiting Not Related to Cancer Therapy: Intractable Problem or Clinical Challenge?

Purpose: Unlike therapy-related nausea and vomiting (chemotherapy or radiotherapy induced), nausea and vomiting (N/V) in patients with advanced cancer is often multicausal and thus presents unique challenges. Few professional guidelines ...

Phase 1 Clinical Trials in the Elderly: Enrollment Challenges

Cancer mostly affects older adults. Despite the increased incidence of cancer among older adults, they are underrepresented in oncology clinical trials. Such trials can provide patients with early access to promising interventions. Clini...

A Patient-Centered Approach for the Treatment of Fungating Breast Wounds

Nearly 2% to 5% of locally advanced breast cancers develop a fungating breast wound (FBW). Fungating breast wounds develop when malignant cells infiltrate the skin and cause breakdown, ulceration, and infection. Although systemic and loc...

Patient-Reported Outcomes and Assessment of Quality of Life: A Focus on Multiple Myeloma

Patients with multiple myeloma are living longer, yet the chronicity of newer treatment modalities has led to increased symptom burden and a notable effect on quality of life (QOL). The assessment of QOL and evaluation of patient-reporte...

Polatuzumab Vedotin for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Transplant-Ineligible Patients

Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma. Although 5-year survival rates in the first-line setting can range from 60% to 70%, up to 50% of patients become refractory or relapse after treatment (Cru...